When anti-CTLA-4 antibody was administered alongside radiation therapy and anti-CD40 mAb therapy, it overcame Treg-mediated immune suppression, resulting in a higher ratio of cytotoxic T cells, tumor rejection, and the development of long-term immunity 189. The gene discussed is CTLA4; the disease is neoplasm.